Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing ...
GlobalData on MSN
Trials to watch: Three major catalysts in Alzheimer’s disease
While Lilly and Eisai/Biogen have validated the amyloid theory, there is an unmet need for drugs with alternative mechanisms ...
The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...
In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, ...
SurvivorNet on MSN
FDA Approves New Subcutaneous (Under-the-Skin) Option for Keytruda: What It Means for Cancer Patients
The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option ...
The FDA approved a supplemental new drug application for Tremfya for the treatment of children aged 6 years or older with ...
The CELEBRATE trial of the novel injectable glycoprotein IIb/IIIa inhibitor zalunfiban (Disaggpro; CeleCor Therapeutics) met ...
The FDA has approved Johnson & Johnson’s TREMFYA for children aged 6+ weighing at least 40 kg with moderate to severe plaque ...
Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing ...
Larimar Therapeutics (LRMR) announced 25 mg and 50 mg data from the ongoing long-term open label study evaluating daily subcutaneous injections of ...
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback